212 related articles for article (PubMed ID: 35322580)
1. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
Zhang X; Trendowski MR; Wilkinson E; Shahbazi M; Dinh PC; Shuey MM; ; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Huddart R; Martin NE; Sanchez VA; Frisina RD; Einhorn LH; Cox NJ; Travis LB; Dolan ME
Cancer Med; 2022 Jul; 11(14):2801-2816. PubMed ID: 35322580
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.
Miaskowski C; Paul SM; Mastick J; Abrams G; Topp K; Smoot B; Kober KM; Chesney M; Mazor M; Mausisa G; Schumacher M; Conley YP; Sabes JH; Cheung S; Wallhagen M; Levine JD
J Pain Symptom Manage; 2018 Jul; 56(1):88-97. PubMed ID: 29524582
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.
Trendowski MR; Wheeler HE; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2020 Dec; 26(24):6550-6558. PubMed ID: 32998964
[TBL] [Abstract][Full Text] [Related]
4. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
Miaskowski C; Mastick J; Paul SM; Abrams G; Cheung S; Sabes JH; Kober KM; Schumacher M; Conley YP; Topp K; Smoot B; Mausisa G; Mazor M; Wallhagen M; Levine JD
J Cancer Surviv; 2018 Apr; 12(2):234-245. PubMed ID: 29159795
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
6. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
7. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.
Miaskowski C; Paul SM; Mastick J; Schumacher M; Conley YP; Smoot B; Abrams G; Kober KM; Cheung S; Henderson-Sabes J; Chesney M; Mazor M; Wallhagen M; Levine JD
Eur J Oncol Nurs; 2018 Feb; 32():1-11. PubMed ID: 29353626
[TBL] [Abstract][Full Text] [Related]
8. Variants in
Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
[No Abstract] [Full Text] [Related]
9. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
Trendowski MR; Baedke JL; Sapkota Y; Travis LB; Zhang X; El Charif O; Wheeler HE; Leisenring WM; Robison LL; Hudson MM; Morton LM; Oeffinger KC; Howell RM; Armstrong GT; Bhatia S; Dolan ME
Cancer; 2021 Nov; 127(21):4091-4102. PubMed ID: 34286861
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
12. Further Investigation of the Role of
Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
[No Abstract] [Full Text] [Related]
13. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
[TBL] [Abstract][Full Text] [Related]
14. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
[TBL] [Abstract][Full Text] [Related]
15. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
JAMA Oncol; 2017 Nov; 3(11):1558-1562. PubMed ID: 28448657
[TBL] [Abstract][Full Text] [Related]
16. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
17. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.
Dolan ME; El Charif O; Wheeler HE; Gamazon ER; Ardeshir-Rouhani-Fard S; Monahan P; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kim J; Fossa SD; Hertz DL; Mushiroda T; Kubo M; Einhorn LH; Cox NJ; Travis LB;
Clin Cancer Res; 2017 Oct; 23(19):5757-5768. PubMed ID: 28611204
[No Abstract] [Full Text] [Related]
19. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.
Travis LB; Fossa SD; Sesso HD; Frisina RD; Herrmann DN; Beard CJ; Feldman DR; Pagliaro LC; Miller RC; Vaughn DJ; Einhorn LH; Cox NJ; Dolan ME;
J Natl Cancer Inst; 2014 Mar; 106(5):. PubMed ID: 24623533
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
